Revenue ($USD): $383,471,000
R&D spend: $74,221,000.00
Employees: 1,100
Fiscal year end: 12/31/22
CEO: Drew Hykes
The company invests aggressively in R&D. In the first half of 2023, Inari grew significantly through new product launches, expansion into global markets and increased adoption of its equipment in medical procedures. Inari this year launched RevCore and T16 Curve, both designed to treat venous thromboembolism, clots in the leg that are often undiagnosed.–BB